During the corresponding time, Asensus Surgical Inc recorded a revenue increase by 53.72 % year on year, sequentially revenue grew by 45.08 %. While revenue at the Asensus Surgical Inc 's corporate clients
Asensus Surgical Inc's Comment on Sales, Marketing and Customers
The Company serves customers worldwide. As of December 31, 2023 and 2022, one customer accounted for 83% and 69% of net accounts receivable, respectively. In 2023, two customers represented 33% and 19% of revenue, while in 2022, one customer accounted for 47% of revenue. The Company assesses customers' financial condition and generally does not require collateral. Accounts receivable are managed with allowances for expected credit losses based on collectability assessments. Inventory management considers historical consumption, forecasted demand, market conditions, and product life cycles. The Company's intellectual property includes purchased patent rights and developed technology from business acquisitions, notably the Senhance System acquired in 2015 and reclassified in 2017, as well as another acquisition in 2018 reclassified in 2020.
Asensus Surgical Receives FDA 510(k) Clearance for Senhance Surgical System in Urology, Showing Promising Growth in Revenue RESEARCH TRIANGLE PARK, N.C. - Asensus Surgical, Inc. (NYSE American: ASXC), a global leader in innovative digital solutions for the operating room, has recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for an expanded indication to treat both adult and pediatric Urology patients with the Senhance Surgical System. This clearance marks a significant achievement for Asensus Surgical as it expands the potential application of its advanced surgical technology to a wider patient population.The Senhance Surgical System is a state-of-the-art robotic surgical p...
Asensus Surgical Inc’s Comment on Sales, Marketing and Customers
The Company serves customers worldwide. As of December 31, 2023 and 2022, one customer accounted for 83% and 69% of net accounts receivable, respectively. In 2023, two customers represented 33% and 19% of revenue, while in 2022, one customer accounted for 47% of revenue. The Company assesses customers' financial condition and generally does not require collateral. Accounts receivable are managed with allowances for expected credit losses based on collectability assessments. Inventory management considers historical consumption, forecasted demand, market conditions, and product life cycles. The Company's intellectual property includes purchased patent rights and developed technology from business acquisitions, notably the Senhance System acquired in 2015 and reclassified in 2017, as well as another acquisition in 2018 reclassified in 2020.
Sources:
Asensus Surgical Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Asensus Surgical Inc’s corporate clients.
For your research, we’ve provided 9 tables on Asensus Surgical Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
